Spravato® (Esketamine)

Spravato (esketamine) is a nasal spray approved by the TGA for treatment-resistant depression. It works differently from traditional antidepressants — rather than acting on serotonin, it targets a different receptor system in the brain involved in learning, memory, and mood regulation. Some patients may notice improvement in mood faster than with conventional antidepressants, though individual responses vary. It is used alongside an oral antidepressant and must be administered under medical supervision. Not all patients will respond, and your psychiatrist will discuss expected outcomes and risks with you.

Yes. Spravato is listed on the Pharmaceutical Benefits Scheme (PBS) for treatment-resistant depression in adults who have not responded adequately to at least two different antidepressant treatments in the current episode. Under PBS listing, the patient contribution is significantly reduced. Your psychiatrist must apply for PBS authority for each treatment course.

Spravato is self-administered as a nasal spray under direct medical supervision. Each session takes approximately two hours: the nasal spray is administered in the first few minutes, followed by a mandatory monitoring period of at least two hours during which blood pressure is checked and you are observed for side effects. Common side effects include temporary dissociation, dizziness, nausea, and increased blood pressure. You must not drive or operate heavy machinery on the day of treatment and will need someone to take you home.

While the Spravato nasal spray must be administered in person under medical supervision, Halcyon Health uses a regional satellite hub model to extend access beyond major cities. This means the initial psychiatric assessment, treatment planning, and ongoing follow-up can be conducted via telehealth, while the actual Spravato administration sessions are arranged at a supervised clinical location near you.